The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 70.1% in November

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 421,900 shares, a growth of 70.1% from the October 31st total of 248,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 0.4 days. Approximately 1.1% of the company’s shares are short sold.

Oncology Institute Trading Down 4.7 %

TOI stock traded down $0.01 during midday trading on Friday, reaching $0.16. 1,117,426 shares of the company’s stock traded hands, compared to its average volume of 416,743. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $2.50. The business has a 50-day moving average price of $0.28 and a two-hundred day moving average price of $0.39. The company has a market capitalization of $12.24 million, a P/E ratio of -0.21 and a beta of 0.60.

Hedge Funds Weigh In On Oncology Institute

Several hedge funds and other institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC raised its holdings in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after buying an additional 53,382 shares during the period. Renaissance Technologies LLC grew its position in Oncology Institute by 142.3% in the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after acquiring an additional 199,300 shares in the last quarter. Finally, Tiff Advisory Services LLC raised its stake in shares of Oncology Institute by 235.1% during the second quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after purchasing an additional 995,280 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.